A drug-resistant fungus that barely existed two decades ago has infected more than 13,500 hospital patients across America in just three years.
Quick Take
- Candida auris clinical cases jumped from 2,882 in 2022 to 6,197 in 2024, according to the Centers for Disease Control and Prevention (CDC).
- The fungus can resist multiple antifungal drug classes, with some strains fighting off nearly every known treatment.
- The World Health Organization (WHO) now lists it among the most dangerous fungal pathogens on Earth.
- Hospitals and nursing homes are the main breeding grounds, and scientists point to warming temperatures as a likely reason it emerged at all.
Case Numbers Have More Than Doubled Since 2022
Federal health data shows a disease that is spreading fast inside American healthcare facilities. The CDC recorded 13,507 clinical cases of Candida auris between 2022 and 2024, with yearly totals more than doubling in that span. The agency says infections have been climbing steadily since 2016, when the fungus first showed up on the CDC’s radar in meaningful numbers.
Candida auris mostly targets people who are already sick. It spreads in hospitals, nursing homes, and long-term care facilities, often through contaminated surfaces or medical equipment. Healthy people rarely catch it. But for patients with weakened immune systems, breathing tubes, or central lines, it can turn deadly fast, and it clings to skin and surfaces longer than most germs doctors routinely fight.
A Fungus That Shrugs Off Standard Drugs
What makes this organism especially alarming is its ability to dodge treatment. The CDC calls it potentially multidrug-resistant, and some strains found in the United States resist three entire classes of antifungal medicine at once: azoles, echinocandins, and polyenes. That leaves doctors with few, if any, backup options when first-line drugs fail.
The scale of that resistance is measurable, not anecdotal. CDC testing of more than 24,000 isolates found over 93 percent resistant to fluconazole, a commonly used antifungal. Resistance to echinocandins, the drug class considered the last reliable defense, stayed far lower at just over 1 percent. That distinction matters. The fungus is not yet untreatable across the board, but it is closing in on one major drug family already.
Global Health Officials Put It on the Priority List
The World Health Organization does not hand out warnings lightly. In 2022, it named 19 fungal pathogens as major public health threats and placed Candida auris in the smallest, most serious group: critical priority. That group also includes Aspergillus fumigatus and Cryptococcus neoformans, fungi tied to severe lung and brain infections in vulnerable patients.
Candida auris stands out because of how new it is. Researchers first identified it as a distinct human pathogen in the late 2000s. Within a few years, genetically different versions of it popped up independently on multiple continents, a pattern that still puzzles scientists studying how it emerged and spread so quickly.
Why a Warming Climate Keeps Coming Up
Infectious-disease experts have floated a theory that connects the dots: a warming planet. Fungi generally cannot survive human body temperature, which is why fungal infections in humans were historically rare compared to bacteria and viruses. Some researchers believe rising global temperatures are helping certain fungal species adapt to heat they once could not tolerate, potentially explaining how Candida auris crossed into humans in the first place.
That theory is plausible and taken seriously by public health researchers, but it remains a proposed driver rather than a fully proven cause. No study cited by health agencies has yet quantified exactly how much warming contributed to this fungus’s rise versus other factors like global travel or hospital transmission networks. The climate link deserves attention, not blind acceptance as settled fact.
What This Means for Patients and Hospitals Now
None of this means every hospital stay now carries fungal risk. Candida auris remains concentrated in specific settings: intensive care units, ventilator wards, and facilities housing medically fragile patients for extended periods. For most Americans, exposure risk stays low. But for families with loved ones in long-term care, understanding the threat helps them ask sharper questions about infection control practices.
The rising case counts partly reflect better detection, since the CDC’s surveillance network has expanded alongside the numbers themselves. That does not make the underlying trend fake. More testing catches more real infections, and the drug-resistance data stands on its own regardless of how aggressively labs go looking for it. The warning from health officials is grounded in hard numbers, not speculation.
CDC 2026 Antimicrobial Resistance Threats Report
9.7 Million Infections. 50,800 Deaths
Antimicrobial resistance (AR), also known as drug resistance, is an urgent global public health threat. AR happens when pathogens (germs) like bacteria and fungi develop the ability to…
— Health Watch USA (@healthwatchusa) October 27, 2026
Antifungal drug development has lagged far behind antibiotic research for decades, leaving doctors with a thin arsenal against organisms like this one. Closing that gap, and keeping hospitals vigilant about screening high-risk patients, now looks less like caution and more like necessity.
Sources:
time.com, cdc.gov, mendeley.com, seattletimes.com
